# Hefei National Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hefei-national-biotech

- Industry: Biotechnology
- Headquarters: Hefei, China
- Website: www.haninspector.com
- Latest round: Series A (Jun 4, 2025)
- Investors on record: 3

## About

Based in Hefei, China, and founded in 2020, Hefei National Biotech specializes in advanced molecular diagnostics and immunodiagnostics. It has acquired High-Tech Enterprise Certificate. The founder, Xiuqing Gong, graduated with a PhD from the Hong Kong University of Science and Technology. The core team members come from Imperial College London, Waseda University in Japan, Hong Kong University of Science and Technology, etc. In June 2025, Hefei National Biotech raised an undisclosed amount of series A funding from new investors Feixi Urban and Rural Construction Investment, Guoyuan Fund and returning investor Hefei High-tech Venture Capital.

Hefei National Biotech specializes in molecular diagnostics and immunodiagnostics, leveraging bio-microfluidic chip technology as its core platform. The company’s flagship products include the GY-100A and GY-200A single-molecule immunoanalysers, which deliver high-precision diagnostic results for various medical conditions, particularly cancer. Their product offerings also feature test kits for prostate cancer (PSA) and cytokine triad tests, addressing specific needs in cancer screening and cytokine profiling.  The company generates revenue by developing molecular in vitro diagnosis and detection technology.

## Funding rounds

- Series A, Jun 4, 2025 — Feixi Urban and Rural Construction Investment, Zhejiang Hengbang Venture Capital, Guoyuan Fund

## Investors

- Feixi Urban and Rural Construction Investment — Series A
- Zhejiang Hengbang Venture Capital — Series A
- Guoyuan Fund (https://capitalatlas.ai/funds/guoyuan-fund) — Series A